First-Line NSCLC Without Driver Mutations: Practice, Gaps, and Costs

Interview: What are the first-line treatment options for NSCLC without driver mutations – and how do cost, histology, and PD-L1 levels shape decisions in practice? Senior consultant in Lung Medicine Ronny Öhman shares insights from Swedish clinical experience.